1354567-97-7

Upstream product

• 500791-70-8 5-amino-2-n-butyl-3-[4-(3-di-n-butylamino propoxy)benzoyl]benzofuran bisoxalate 
• 141627-42-1 (2-butyl-5-nitrobenzofuran-3-yl)(4-methoxyphenyl)methanone 
• 141625-93-6 dronedarone hydrochloride 
• 141645-16-1 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran 
• 133238-87-6 2-(n-butyl)-5-nitrobenzofuran 
• 100-07-2 4-methoxy-benzoyl chloride 
• 141644-91-9 (5-amino-2-butyl-benzofuran-3-yl)-[4-(3-dibutylamino-propoxy)-phenyl]-methanone 
• 141645-23-0 (2-butyl-5-nitrobenzofuran-3-yl)(4-(3-(dibutylamino)propoxy)phenyl)methanone 

Relevant academic research and scientific papers

PROCESSES FOR PREPARING DRONEDARONE AND ITS INTERMEDIATES

The invention relates to process for the preparation of benzofuran derivative and intermediates thereof. More particularly, it relates to processes for the preparation of dronedarone or pharmaceutically acceptable acid addition salts thereof in crystalline form. The invention also relates to pharmaceutical compositions that include the dronedarone hydrochloride in crystalline form substantially free from disulfonamide impurity.

PROCESS FOR PREPARATION OF N-[2-BUTYL-3-[4-[3-(DIBUTYLAMINO)PROPOXY]BENZOYL]-5-BENZOFURANYL]METHANESULFONAMIDE, ACID ADDITION SALTS AND PRODUCT THEREOF

The present invention relates to a process for the preparation of highly pure N-[2- butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5- benzofuranyljmethanesulfonamide and pharmaceutically acceptable salts thereof having HPLC purity greater than 99.5%.